Related Experiment Videos
[Anaplastic large-cell lymphoma: review].
R Kodet1, M Mrhalová, L Krsková
1Ustav patologie a molekulární medicíny 2. lékarské fakulty Univerzity Karlovy a Fakultní nemocnice v Motole, Praha. roman.kodet@lfmotol.cuni.cz
Ceskoslovenska Patologie
|November 25, 2003
Summary
Anaplastic large cell lymphomas (ALCLs) are aggressive T-cell cancers. Diagnosis uses morphology and immunohistochemistry, classifying ALCLs by anaplastic lymphoma kinase (ALK) expression, impacting prognosis and treatment.
Area of Science:
- Hematology
- Oncology
- Immunohistochemistry
Background:
- Anaplastic large cell lymphomas (ALCLs) are a diverse group of malignant lymphoproliferative diseases.
- Most ALCLs are T-cell derived, characterized by cytotoxic granule protein expression (perforin, granzyme B, TIA-1).
Purpose of the Study:
- To outline the diagnostic and prognostic stratification of ALCLs.
- To differentiate ALK-positive and ALK-negative ALCL subtypes.
Main Methods:
- Morphological assessment and immunohistochemistry (IHC) for CD30 and ALK protein expression.
- Cytogenetic analysis including FISH for ALK gene rearrangements.
- Molecular detection of specific chimeric genes (e.g., NPM-ALK) for diagnosis and minimal residual disease monitoring.
Main Results:
- ALCLs are classified into ALK-positive (affecting younger patients) and ALK-negative (affecting older patients) subtypes.
- ALK-positive ALCLs generally respond well to treatment and have a more favorable prognosis.
- Primary cutaneous ALCLs often follow an indolent course without systemic spread.
Conclusions:
- Diagnostic strategies combining morphology, IHC, and molecular techniques are crucial for ALCL subtyping.
- ALK status is a key determinant of prognosis and treatment response in ALCL.
- Further research is needed to validate molecular findings in broader patient populations.